We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Senate Health, Education, Labor and Pensions (HELP) Committee has scheduled a vote on the nomination of Andrew von Eschenbach to be the FDA commissioner for Sept. 20.
In response to a rising number of pediatric clinical trials, the FDA is adding an ethicist to the staff of its Office of Pediatric Therapeutics in an effort to ensure protections for children.
The Senate Health, Education, Labor and Pensions Committee (HELP) has scheduled a vote on the nomination of Andrew von Eschenbach to be the FDA commissioner for Sept. 20.
Centers for Medicare & Medicaid Services head Mark McClellan became the latest Bush staffer to leave when he announced Sept. 5 that he will resign in early October, saying it was a “good time for a transition,” with the agency’s programs in a “fundamentally good position.”
Pfizer’s board of directors has named Jeffrey Kindler as the company’s CEO, taking the place of Hank McKinnell, who will remain chairman of the board until next February.